Gastroenterology Research and Practice最新文献

{"title":"The Role of Key Molecules of Pyroptosis in Liver Damage of Rats With Exertional Heat Stroke.","authors":"Lifang Lin, Jiaolong Zheng, Qingqing Lin, Fangze Cai, Dongliang Li","doi":"10.1155/grp/6864091","DOIUrl":"10.1155/grp/6864091","url":null,"abstract":"<p><p><b>Purpose:</b> This study is aimed at investigating the role of key molecular elements involved in pyroptosis in liver injury caused by exertional heat stroke (EHS). <b>Methods:</b> We established a model of EHS-induced liver injury in Sprague-Dawley rats, with a control group (receiving no treatment) for comparison and 12 rats in each group. Alanine transaminase (ALT) and aspartate transaminase (AST) levels in the blood were detected. Interleukin-1 beta (IL-1<i>β</i>) and interleukin-18 (IL-18) levels were assessed using enzyme-linked immunosorbent assays (ELISA). Pathological changes in liver tissue were examined by hematoxylin and eosin (H&E) staining. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to detect mRNA and protein expression levels of Caspase-1 and Gasdermin D. <b>Results:</b> Compared to the control group, the liver tissue of the EHS group showed congestion in hepatic sinusoids, hepatocyte edema, eosinophilic changes, necrosis, and infiltration of inflammatory cells. ALT and AST levels in the EHS group were significantly higher than those in the control group (<i>p</i> < 0.05). The mRNA expressions of Caspase-1, Gasdermin D, IL-1<i>β</i>, and IL-18 were significantly increased in the EHS group compared to the control group (<i>p</i> < 0.001). The protein expressions of Caspase-1, cleaved Caspase-1, Gasdermin D, and cleaved Gasdermin D were significantly increased in the EHS group. <b>Conclusion:</b> These findings indicated that hepatic pyroptosis plays an important role in EHS-induced liver injury.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2025 ","pages":"6864091"},"PeriodicalIF":2.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Incidence and Clinical Characteristics of COVID-19 in Children With IBD During the Omicron Wave: A Single-Center Experience in China.","authors":"Rui Li, Pei-Yu Chen, Hui-Wen Li, Lu Ren, Yang Cheng, Li-Ying Liu, Li-Juan Wei, Zi-Huan Zeng, Wan-Fu Xu, Si-Tang Gong, Lan-Lan Geng","doi":"10.1155/grp/1868214","DOIUrl":"10.1155/grp/1868214","url":null,"abstract":"<p><p><b>Background and Aims:</b> The pandemic of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide, including the pediatric inflammatory bowel disease (PIBD) patients. As no study has investigated the susceptibility and disease course of COVID-19 in PIBD patients after the end of zero-COVID policy in China, we conducted a retrospective cross-sectional study in our center. <b>Methods:</b> A cross-sectional survey enrolling PIBD patients has been completed by online survey, phone, and face-to-face assessment. The demographic data, epidemiological characteristics, clinical manifestations, treatment, and prognosis of the patients were analyzed. <b>Results:</b> PIBD patients represented 55.45% (56/101) of SARS-CoV-2-positive cases between December 1st 2022 and January 31st 2023; 67.86% were male; the mean age was 11.15 ± 3.92 years old. Among the SARS-CoV-2-positive cases, three patients (5.36%) were asymptomatic, and 53 patients (94.64%) had mild symptoms. The main symptoms were fever (92.86%), cough (69.64%), nasal congestion or running nose (35.71%), and sore throat (33.93%). No severe case or deaths were reported. All patients recovered from COVID-19 symptoms within 1 week. We found no significant association between the type of inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis, and unclassified) and SARS-CoV-2 infection rates, nor did we observe any correlation between different treatments and the risk of infection. Fifty-one patients were reported to be in close contact with persons confirmed with COVID-19 infection, and out of them, 36 patients test positive for SARS-CoV-2, which is significantly higher than that in patients without exposure to COVID-19 (70.59% vs. 33.33%, <i>p</i> = 0.002). A total of 10 patients were underweight, of which nine patients tested positive for COVID-19 (90% vs. 51.65%, <i>p</i> = 0.048). Meanwhile, unvaccinated patients were also found to be more susceptible to SARS-CoV-2 than vaccinated patients (70.97% vs. 48.48%, <i>p</i> = 0.049). The multivariable analysis showed that patients with moderate/severe activity of IBD were associated with an increased risk of SARS-CoV-2 infection (odds ratio (OR), 1.12; 95% confidence interval (CI), 1.13-8.33, <i>p</i> = 0.028). <b>Conclusions:</b> The incidence of SARS-CoV-2 infection in our center of PIBD patients during the Omicron pandemic was 55.45%. No severity or death case was observed. The incidence was higher in underweight and unvaccinated IBD children. Patients with moderate/severe activity of IBD were at a higher risk of SARS-CoV-2 infection.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2025 ","pages":"1868214"},"PeriodicalIF":2.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Symptoms in Patients With Heterotopic Gastric Mucosa in the Upper Esophagus.","authors":"Zhenxiang Wang, Ying Chen, Huihui Sun, Jie Xiong, Yu Zeng, Ye Chen, Yan Zhang, Zhiyu Dong, Junwen Wang, Guangbing Duan, Bo Li, Xue Qian, Kejing Sun, Tingting Zhan, Yuanxi Jiang, Shuchang Xu","doi":"10.1155/grp/7658517","DOIUrl":"10.1155/grp/7658517","url":null,"abstract":"<p><p><b>Goal:</b> This study is aimed at comparing the clinical characteristics and histological types of symptomatic and asymptomatic patients with heterotopic gastric mucosa in the upper esophagus (HGMUE) and exploring the factors influencing the occurrence and severity of laryngopharyngeal reflux (LPR) symptoms in these patients. <b>Background:</b> HGMUE is a potential cause of LPR symptoms. <b>Study:</b> This retrospective analysis evaluated 70 patients with HGMUE using a detailed questionnaire. Clinical, histological, high-resolution manometry, and 24-h pH impedance monitoring data were compared between symptomatic (<i>n</i> = 49) and asymptomatic (<i>n</i> = 21) patients. <b>Results</b>: The diameter of HGMUE was significantly larger in the symptomatic group (<i>p</i> < 0.05), and the incidence of LPR symptoms increased with larger diameter grades; male patients were more likely to have LPR symptoms. The incidence of LPR symptoms varied significantly across histological classifications, being highest in patients with the fundic type (<i>χ</i> ² = 6.64, <i>p</i> < 0.05). Binary logistic regression analysis identified sex and histological type as risk factors for LPR symptoms, with odds ratios of 8.996 (95% confidence interval (CI): 1.350-59.962) and 8.493 (95% CI: 1.486-48.522), respectively. The mean nocturnal baseline impedance (MNBI) in the upper esophagus was significantly lower in the symptomatic group (1676.82 ± 739.09 <i>Ω</i> vs. 2441.01 ± 604.11 <i>Ω</i>; <i>p</i> < 0.05). Clinical and demographic characteristics did not significantly affect the severity of LPR symptoms. <b>Conclusion:</b> The diameter, histological type, and sex of patients are risk factors for the occurrence of LPR symptoms in patients with HGMUE. More attention should be paid to patients with these factors. The MNBI is an effective indicator of the symptoms and treatment.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2025 ","pages":"7658517"},"PeriodicalIF":2.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FTO Alleviates Hepatic Ischemia-Reperfusion Injury by Regulating Apoptosis and Autophagy.","authors":"Pi-Xiao Wang, Ling Zhu, Mei Xiang, Rixin Zhang, Xiaolin Zheng, Zhi Zheng, Kai Li","doi":"10.1155/grp/5587859","DOIUrl":"10.1155/grp/5587859","url":null,"abstract":"<p><p><b>Objective:</b> Despite N⁶-methyladenosine (m⁶A) being closely involved in various pathophysiological processes, its potential role in liver injury is largely unknown. We designed the current research to study the potential role of fat mass and obesity-associated protein (FTO), an m⁶A demethylase, on hepatic ischemia-reperfusion injury (IRI). <b>Methods:</b> Wild-type mice injected with an adeno-associated virus carrying fat mass and obesity-associated protein (AAV-FTO) or adeno-associated virus carrying green fluorescent protein (GFP) (AAV-GFP) were subjected to a hepatic IRI model in vivo. Hematoxylin-eosin staining was performed to observe IRI. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was used to observe the cell apoptosis. Reverse transcription polymerase chain reaction (RT-PCR) was used to observe the expression of FTO. The protein levels of FTO, apoptosis, or autophagy-associated signaling proteins were detected by western blot. Reactive oxygen species (ROS) levels were determined by flow cytometry, and immunohistochemistry was used to detect the FTO and LC3-II expression. For in vitro experiments, cultured hepatocytes were subjected to hypoxia/reoxygenation (H/R) stimulation. Monodansylcadaverine (MDC) staining was used to visualize autophagic vesicles. <b>Results:</b> In the present study, we showed that FTO was involved in hepatic IRI, apoptosis, and autophagy. Specifically, the expression level of FTO was significantly reduced in the hepatic IRI. Besides, increasing FTO expression (AAV-FTO) ameliorated the hepatic IRI in animal models, accompanied by decreased apoptosis and autophagy. Furthermore, the FTO inhibitor (FB23-2) aggravated autophagy in hepatocytes upon H/R-induced damage. <b>Conclusion:</b> FTO could act as a protective effector during hepatic IRI, associated with decreased apoptosis and autophagy. FTO-mediated m⁶A demethylation modification may be an important therapeutic target for hepatic IRI.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2025 ","pages":"5587859"},"PeriodicalIF":2.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External Validation of SHA₂PE Score: A Score to Predict Low-Risk Lower Gastrointestinal Bleeding in the Emergency Department.","authors":"Akram I Ahmad, Ahmed El Sabagh, Jennie Zhang, Claire Caplan, Ahmad Al-Dwairy, Tarek Bakain, Faith Buchanan, Lea Fisher, Andrew Wilbur, Samantha Marshall, Garrett Buechner, Malaak Hamzeh, Rachna Dhanjal, Alexander Boos, Lynette Sequeira","doi":"10.1155/grp/5657404","DOIUrl":"10.1155/grp/5657404","url":null,"abstract":"<p><p><b>Introduction:</b> Lower gastrointestinal bleeding (LGIB) frequently leads to emergency department (ED) visits and hospitalizations, encompassing a spectrum of outcomes from spontaneous resolution to intrahospital mortality. <b>Aim:</b> The purpose of this study was to validate a scoring system designed to identify cases of low-risk LGIB, allowing for safe discharge from the ED. <b>Methods:</b> A retrospective analysis of all gastrointestinal bleeding cases presented at three EDs in 2020 was conducted, focusing specifically on patients with LGIB. The SHA₂PE score incorporates factors such as systolic blood pressure, hemoglobin levels, use of antiplatelet or anticoagulant medications, pulse rate, and episodes of bright blood per rectum. <b>Results:</b> Out of 1112 patients presenting with LGIB to the ED, 55 were hospitalized, 20 required blood transfusions, 15 underwent colonoscopies, one underwent interventional radiology procedures, and two patients died. Employing a SHA₂PE score with a cutoff value of 1 yielded a specificity of 78.5% (95% CI (confidence interval) [75.8-81.0]), sensitivity of 76.8% (95% CI [63.6-87.0]), positive predictive value (PPV) of 17.0% (95% CI [12.6-22.2]), and negative predictive value (NPV) of 98.3% (95% CI [97.2-99.1]) for predicting the need for hospitalization and intrahospital intervention. When considering return visits to the ED within 7 days with the same presentation, the score demonstrated a specificity of 78.8% (95% CI [76.0-81.3]), sensitivity of 68.6% (95% CI [56.4-79.1]), PPV of 19% (95% CI [14.3-24.4]), and NPV of 97.2% (95% CI [95.8-98.2]). <b>Conclusions:</b> The SHA₂PE score demonstrates potential in predicting cases of low-risk LGIB, offering a high NPV for hospitalization, the need for intrahospital intervention, and return visits to the ED. However, these findings should be interpreted cautiously given the low prevalence of interventions and limitations in the study's population and design.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2025 ","pages":"5657404"},"PeriodicalIF":2.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11723982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the Power of Physical Activity in Inflammatory Bowel Disease: A Comprehensive Review.","authors":"Jiajia Chen, Shaopeng Sun","doi":"10.1155/grp/7138811","DOIUrl":"https://doi.org/10.1155/grp/7138811","url":null,"abstract":"<p><p><b>Purpose of Review:</b> This study reviewed the concept and assessment tools of physical activity (PA), the level and limiting factors of PA in people with inflammatory bowel disease (IBD), and its impact on patient clinical outcomes, aimed at providing a reference for exercise-assisted treatment of people with IBD. <b>Recent Findings:</b> The current findings of PA in patients with IBD focus on the risk of disease, promoting and limiting factors, and the effect of clinical outcomes. Patients with IBD have inadequate levels of PA, and the association of PA with IBD incidence and disease activity remains controversial. Nevertheless, PA has demonstrated beneficial effects on clinical outcomes, particularly in reducing mortality, enhancing quality of life, and improving body composition. <b>Summary:</b> IBD is a chronic disease with no cure. Although medication is the main treatment modality, it requires careful consideration of its risks and benefits. PA has proven to be an effective nondrug treatment that can slow the progression of various chronic diseases and enhance patients' quality of life. However, the correlation between PA levels and clinical outcomes of IBD remains unclear.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2024 ","pages":"7138811"},"PeriodicalIF":2.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etiology and Prognostic Criteria for Liver Failure in Southeast China: A Multicenter Retrospective Cohort Study Between 2018 and 2020.","authors":"Chunyan Lyu, Jun Han, Naling Kang, Dawu Zeng, Chantsalmaa Davgadorj, Lina Ge, Meifang Zhou, Richeng Mao, Yan Yan","doi":"10.1155/grp/5512889","DOIUrl":"10.1155/grp/5512889","url":null,"abstract":"<p><p><b>Background:</b> The prognosis of patients with liver failure (LF) depends significantly on the etiology and clinical indicators. This analysis of these basic indicators can help provide a basis for the study of predictive outcome indicators. <b>Methods:</b> We collected the data from multiple centers in Southeast China, including subclasses of acute liver failure (ALF), subacute liver failure (SLF), acute-on-chronic liver failure (ACLF), subacute-on-chronic liver failure (SALF), and chronic liver failure (CLF). Multivariate logistic regression analysis was used to screen for clinical indicators of nonsurvivors. We analyzed receiver operating characteristic (ROC) curves and cutoff values to assess the prognostic criteria. <b>Results:</b> Hepatitis B virus (HBV) infection is the leading etiology of patients with LF (64.52% (411/637)). SALF (41.36%) and CLF (32.30%) are the main subclasses of the hepatitis B virus-related liver failure (HBV-LF) group and the non-HBV-related LF group in Southeast China, respectively. Between 2018 and 2020, the incidence of HBV-LF decreased significantly, ranging from 72.36% to 59.74%, and the spontaneous survival rates of patients with HBV-LF were substantially lower than those of non-HBV-LF patients (36.43%~44.93% vs. 58.97%~63.64%). Infection and cirrhosis were the leading causes of death in both groups. The age and total bilirubin value of the nonsurvivors with HBV-LF were significantly higher, and the number of days of hospitalization was significantly shorter than that of the survivors. The ages of the nonsurvivors in the non-HBV-LF group were significantly higher than those of the survivors. The prothrombin time-international normalized ratio (PT-INR) is 2.05, 1.92, or 2.11, and antithrombin III (AT III) is 24.50%, which are proposed as prognostic criteria for the HBV-SALF (hepatitis B virus-related subacute-on-chronic liver failure), non-HBV-SLF (non-hepatitis B virus-related subacute liver failure), non-HBV-ACLF (non-hepatitis B virus-related acute-on-chronic liver failure), and HBV-ALF (hepatitis B virus-related acute liver failure) subclasses, respectively. <b>Conclusions:</b> The incidence of HBV-LF is decreasing annually. AT III, as an independent prognostic criterion, has excellent discriminative ability for the outcomes of the HBV-ALF subclass.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2024 ","pages":"5512889"},"PeriodicalIF":2.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Efficacy of Vibration-Controlled Transient Elastography in Patients With Metabolic Dysfunction-Associated Liver Disease and Chronic Hepatitis B.","authors":"Yaoyu Liu, Zhizhen Huang, Xinya Lan, Min Jia, Xiaoting Zheng, Min Hu, Huiying Luo, Luyun Zhang, Xuejing Li, Shaodong Chen, Yunru Li, Huiqing Liang","doi":"10.1155/grp/6722810","DOIUrl":"10.1155/grp/6722810","url":null,"abstract":"<p><p><b>Aim of the Study:</b> HBV-infected individuals are also presenting with MASLD. However, the value of VCTE for detecting hepatic fibrosis and steatosis in CHB patients concurrent with MASLD is unclear. In patients with combined CHB and MASLD, we intend to assess the diagnostic efficacy of VCTE in determining the extent of fibrosis and steatosis. <b>Methods:</b> This retrospective study involved 368 patients diagnosed with chronic HBV infection combined with MASLD who received liver biopsy and VCTE at Xiamen City Traditional Chinese Medicine Hospital from June 2018 to June 2023. The cutoff values for liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) were determined via the use of the cross-validated area under the receiver operating characteristic (AUROC) curve analyses to identify pairwise fibrosis stage and grade, respectively. The diagnostic statistics were calculated with a 90% fixed sensitivity and 90% specificity. <b>Results:</b> An AUROC of 0.86 (95% CI: 0.76-0.95) was determined by a LSM cutoff value of 11.25 to identify patients with cirrhosis. Patients have the following values: sensitivity, 0.79; specificity, 0.90; PPV, 0.89; and NPV, 0.81. An AUROC of 0.84 (95% CI: 0.76-0.95) was determined by a CAP cutoff value of 313 to identify patients with severe steatotic liver. Patients have the following values: sensitivity, 0.86; specificity, 0.82; PPV, 0.82; and NPV, 0.85. <b>Conclusion:</b>In this investigation of adult patients diagnosed with CHB with MASLD, VCTE demonstrated a robust capability to differentiate cirrhosis and severe steatotic liver.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2024 ","pages":"6722810"},"PeriodicalIF":2.0,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Gastroparesis and the Impact of Metformin in Diabetic Patients: A Cross-Sectional Study in Riyadh, Saudi Arabia.","authors":"Jehad A Aldali, Mushabbab K Asseri, Haneen A Almufarrij, Aroob M Alromih, Albandari M Alajlan, Khawlah A Alrashed, Atheer I ALghadeer, Bushra I Almutawa, Abdulrahman Alshalani","doi":"10.1155/grp/3713569","DOIUrl":"10.1155/grp/3713569","url":null,"abstract":"<p><p><b>Background:</b> The prevalence of gastroparesis in individuals with diabetes mellitus varies significantly across different studies. This study is aimed at estimating the prevalence of gastroparesis among diabetic patients in Riyadh, Saudi Arabia, and evaluating the association between metformin use and clinical manifestations of gastroparesis. <b>Methods:</b> This cross-sectional study employed an online survey distributed via Google Forms, targeting patients at a diabetes clinic. The survey comprised three sections, including the Gastroparesis Cardinal Symptom Index (GCSI). Eligible participants were those diagnosed with either type 1 or type 2 diabetes mellitus and aged 18 or older. <b>Results:</b> The study included 385 participants, with the majority diagnosed with type 2 diabetes (55.6%) for over 10 years (59.5%). A significant proportion had poorly controlled blood glucose levels (56.6%) and were taking metformin (50.9%). Among gastrointestinal (GI) symptoms, \"stomach fullness\" was reported most frequently (53.2%), whereas \"vomiting\" was reported least often (17.9%). GCSI scores did not differ significantly between type 1 and type 2 diabetes patients (<i>p</i> = 0.88). However, patients with diabetes durations of less than 3 years, those with durations of 5-7 years controlled blood glucose levels, and those on metformin exhibited higher GCSI scores (<i>p</i> = 0.20, <i>p</i> = 0.02, and <i>p</i> = 0.10, respectively). <b>Conclusion:</b> This study identified some commonalities as well as differences in the prevalence and symptomatology of gastroparesis among diabetic patients. We observed no significant variation in GCSI scores between type 1 and type 2 diabetes. Nevertheless, higher GCSI scores were associated with shorter diabetes durations, controlled blood glucose levels, and metformin use. However, due to the small sample size and reliance on self-reported data, one should interpret the study's findings with caution.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2024 ","pages":"3713569"},"PeriodicalIF":2.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Practice and Safety of Endoscopic Balloon Dilation for Crohn's Disease-Related Strictures: A Nationwide Claim Database Analysis in Japan.","authors":"Rintaro Moroi, Kunio Tarasawa, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito, Hisashi Shiga, Shin Hamada, Yoichi Kakuta, Kiyohide Fushimi, Kenji Fujimori, Yoshitaka Kinouchi, Atsushi Masamune","doi":"10.1155/2024/1291965","DOIUrl":"10.1155/2024/1291965","url":null,"abstract":"<p><p><b>Introduction:</b> Although endoscopic balloon dilation (EBD) is a common therapeutic approach for managing strictures associated with Crohn's disease (CD), the clinical application and complication rates of EBD remain unclear. <b>Methods:</b> We collected admission data for patients who underwent EBD using a nationwide database. We compared EBD outcomes between ileal and colonic strictures, CD and ulcerative colitis, and CD and anastomotic strictures arising from cancer-related surgery. Subsequently, propensity score matching was employed to facilitate comparisons between each group. <b>Results:</b> The median duration of hospital stay was 4 days. Endoscopic hemostasis and urgent surgery rates after EBD for CD-related strictures were considerably low (0.035% and 0.11%, respectively). Most patients with CD underwent only one EBD procedure during a single admission. Although no significant differences in patient backgrounds and severe complications were observed between ileal and colonic stricture in CD, multiple EBD procedures were more commonly performed for ileal strictures than for colonic stricture. Moreover, EBD for ileal stricture was more frequently conducted in high-volume centers than in low-volume centers. Regarding severe complications after EBD, no significant differences were observed between CD-related strictures and ulcerative colitis or anastomotic strictures related to cancer surgery. <b>Conclusion:</b> Our findings support the safe and effective use of EBD for both ileal and colonic strictures associated with CD. The clinical practice and safety outcomes of EBD for CD-related strictures were comparable to those for strictures stemming from other etiologies.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2024 ","pages":"1291965"},"PeriodicalIF":2.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}